PURE Bioscience, Therapeutics expand silver dihydrogen citrate development deal

By E. Janene Geiss

Philadelphia, May 2 - PURE Bioscience announced Tuesday the expansion of its joint development initiative with Therapeutics, Inc. to include development of PURE's silver dihydrogen citrate broad-spectrum antimicrobial as an active pharmaceutical ingredient in products for treatment of dermatophytoses such as athlete's foot and nail fungus and to develop antimicrobial skin wash products, beginning with a hand sanitizer.

PURE and Therapeutics anticipate filing five formal submissions for Investigational New Drug applications with the Food and Drug Administration over the next 24 months, beginning with an application for the hand sanitizer in the fourth quarter this year, according to a company news release.

In addition to the hand sanitizer, athlete's foot and nail fungus programs, Therapeutics said it already is pursuing silver dihydrogen citrate-based anti-acne and vaginal anti-infective pharmaceutical development programs.

The companies said they anticipate IND filings for bacterial vaginosis, a lead dermatophytoses indication and acne in 2007.

The companies also said that to optimize development of these products, they may also consider development strategies outside of the United States.

Therapeutics is a San Diego-based private research and development company.

PURE, based in El Cajon, Calif., develops and markets technology-based bioscience products that provide non-toxic solutions to numerous global health challenges.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.